These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 29787534)
1. A metal organic framework reduces thrombus formation and platelet aggregation ex vivo. Roberts TR; Neufeld MJ; Meledeo MA; Cap AP; Cancio LC; Reynolds MM; Batchinsky AI J Trauma Acute Care Surg; 2018 Sep; 85(3):572-579. PubMed ID: 29787534 [TBL] [Abstract][Full Text] [Related]
2. Development and Blood Compatibility of a Stable and Bioactive Metal-Organic Framework Composite Coating for Blood-Circulation Tubing. Melvin AC; Wick TV; Zang Y; Harea GT; Cancio LC; Reynolds MM; Batchinsky AI; Roberts TR ACS Biomater Sci Eng; 2022 Aug; 8(8):3438-3449. PubMed ID: 35776832 [TBL] [Abstract][Full Text] [Related]
3. Copper ion vs copper metal-organic framework catalyzed NO release from bioavailable S-Nitrosoglutathione en route to biomedical applications: Direct Tuttle RR; Rubin HN; Rithner CD; Finke RG; Reynolds MM J Inorg Biochem; 2019 Oct; 199():110760. PubMed ID: 31349071 [TBL] [Abstract][Full Text] [Related]
4. Water-Stable Metal-Organic Framework/Polymer Composites Compatible with Human Hepatocytes. Neufeld MJ; Ware BR; Lutzke A; Khetani SR; Reynolds MM ACS Appl Mater Interfaces; 2016 Aug; 8(30):19343-52. PubMed ID: 27447022 [TBL] [Abstract][Full Text] [Related]
5. Tethered-liquid omniphobic surface coating reduces surface thrombogenicity, delays clot formation and decreases clot strength ex vivo. Roberts TR; Leslie DC; Cap AP; Cancio LC; Batchinsky AI J Biomed Mater Res B Appl Biomater; 2020 Feb; 108(2):496-502. PubMed ID: 31069955 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy. Megson IL; Sogo N; Mazzei FA; Butler AR; Walton JC; Webb DJ Br J Pharmacol; 2000 Dec; 131(7):1391-8. PubMed ID: 11090112 [TBL] [Abstract][Full Text] [Related]
7. Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione. Gordge MP; Hothersall JS; Noronha-Dutra AA Br J Pharmacol; 1998 May; 124(1):141-8. PubMed ID: 9630353 [TBL] [Abstract][Full Text] [Related]
8. Metal-Organic Framework/Chitosan Hybrid Materials Promote Nitric Oxide Release from S-Nitrosoglutathione in Aqueous Solution. Neufeld MJ; Lutzke A; Tapia JB; Reynolds MM ACS Appl Mater Interfaces; 2017 Feb; 9(6):5139-5148. PubMed ID: 28164705 [TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of the safe margin, antithrombotic and antiproliferative actions for the treatment of restenosis: Nitric oxide donor and polymers. Sorragi Cde L; Shishido SM; Lemos ME; Marcondes S; Antunes E; Krieger MH Cell Biochem Funct; 2011 Apr; 29(3):207-14. PubMed ID: 21374644 [TBL] [Abstract][Full Text] [Related]
10. Copper-Based SURMOFs for Nitric Oxide Generation: Hemocompatibility, Vascular Cell Growth, and Tissue Response. Zhao Q; Fan Y; Zhang Y; Liu J; Li W; Weng Y ACS Appl Mater Interfaces; 2019 Feb; 11(8):7872-7883. PubMed ID: 30726055 [TBL] [Abstract][Full Text] [Related]
11. The synergism of hydrogen peroxide with plasma S-nitrosothiols in the inhibition of platelet activation. Naseem KM; Chirico S; Mohammadi B; Bruckdorfer KR Biochem J; 1996 Sep; 318 ( Pt 3)(Pt 3):759-66. PubMed ID: 8836116 [TBL] [Abstract][Full Text] [Related]
12. In vitro inhibition of human and rat platelets by NO donors, nitrosoglutathione, sodium nitroprusside and SIN-1, through activation of cGMP-independent pathways. Priora R; Margaritis A; Frosali S; Coppo L; Summa D; Di Giuseppe D; Aldinucci C; Pessina G; Di Stefano A; Di Simplicio P Pharmacol Res; 2011 Sep; 64(3):289-97. PubMed ID: 21539916 [TBL] [Abstract][Full Text] [Related]
13. S-nitrosoglutathione preserves platelet function during in vitro ventricular assist device circulation. Aledia AS; Tran LM; King BO; Serna DL; Eng J; Jones BU; Chen JC; Roum JH ASAIO J; 2002; 48(5):526-31. PubMed ID: 12296574 [TBL] [Abstract][Full Text] [Related]
14. [Effect of nitric oxide on the cryopreservation of platelets]. Lee JH; Kim JT; Cho YG Korean J Lab Med; 2008 Apr; 28(2):136-43. PubMed ID: 18458510 [TBL] [Abstract][Full Text] [Related]
15. Surface-Catalyzed Nitric Oxide Release via a Metal Organic Framework Enhances Antibacterial Surface Effects. Garren M; Maffe P; Melvin A; Griffin L; Wilson S; Douglass M; Reynolds M; Handa H ACS Appl Mater Interfaces; 2021 Dec; 13(48):56931-56943. PubMed ID: 34818503 [TBL] [Abstract][Full Text] [Related]
16. Nitric oxide releasing Tygon materials: studies in donor leaching and localized nitric oxide release at a polymer-buffer interface. Joslin JM; Lantvit SM; Reynolds MM ACS Appl Mater Interfaces; 2013 Oct; 5(19):9285-94. PubMed ID: 23957655 [TBL] [Abstract][Full Text] [Related]
17. Construction and evaluation of nitric oxide generating vascular graft material loaded with organoselenium catalyst via layer-by-layer self-assembly. An J; Chen S; Gao J; Zhang X; Wang Y; Li Y; Mikhalovsky S; Kong D; Wang S Sci China Life Sci; 2015 Aug; 58(8):765-72. PubMed ID: 26014212 [TBL] [Abstract][Full Text] [Related]
18. Monitoring a MOF Catalyzed Reaction Directly in Blood Plasma. Tuttle RR; Daly RE; Rithner CD; Reynolds MM ACS Appl Mater Interfaces; 2021 Nov; 13(44):52006-52013. PubMed ID: 34280308 [TBL] [Abstract][Full Text] [Related]
19. Nitric Oxide Generation from Endogenous Substrates Using Metal-Organic Frameworks: Inclusion within Poly(vinyl alcohol) Membranes To Investigate Reactivity and Therapeutic Potential. Neufeld MJ; Lutzke A; Jones WM; Reynolds MM ACS Appl Mater Interfaces; 2017 Oct; 9(41):35628-35641. PubMed ID: 28976734 [TBL] [Abstract][Full Text] [Related]
20. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model. Vilahur G; Segalés E; Salas E; Badimon L Circulation; 2004 Sep; 110(12):1686-93. PubMed ID: 15381660 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]